New combo aims to boost immunotherapy in elderly melanoma patients
NCT ID NCT07644897
First seen Jun 14, 2026 · Last updated Jun 22, 2026 · Updated 1 time
Summary
This Phase 2 trial tests whether adding thymosin alpha 1 to the immunotherapy drug toripalimab can help elderly patients (60+) with advanced melanoma. The study will enroll 55 participants and measure how many patients' tumors shrink or disappear. Researchers also want to see if the combination is safer and better tolerated than standard treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nanshan hospital
RECRUITINGShenzhen, Guangdong, 518000, China
Contact
-
Sun yat-sen uniersity
RECRUITINGGuangzhou, Guangdong, 510000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Thymosin alpha 1 and toripalimab (anti-PD-1 antibody)
What this could lead to
If it works, this combination could offer a safer, more effective treatment option for elderly patients with advanced melanoma who cannot tolerate standard therapies.
What could go wrong
This is a small, early-phase, single-arm trial with no control group, so results may not be conclusive. The combination may not improve outcomes and could still cause side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.